Genes Tech Group Holdings Company Limited Logo

Genes Tech Group Holdings Company Limited

8257.HK

(1.2)
Stock Price

0,06 HKD

3.07% ROA

7.77% ROE

7.93x PER

Market Cap.

489.670.500,00 HKD

78.89% DER

0% Yield

6.1% NPM

Genes Tech Group Holdings Company Limited Stock Analysis

Genes Tech Group Holdings Company Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Genes Tech Group Holdings Company Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.38x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock maintains a fair debt to equity ratio (86%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (3), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

5 ROE

Negative ROE (-10.29%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-3.57%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Genes Tech Group Holdings Company Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Genes Tech Group Holdings Company Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Genes Tech Group Holdings Company Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Genes Tech Group Holdings Company Limited Revenue
Year Revenue Growth
2014 685.966.000
2015 1.025.919.000 33.14%
2016 1.223.294.000 16.13%
2017 1.238.370.000 1.22%
2018 1.122.046.000 -10.37%
2019 1.908.210.000 41.2%
2020 1.497.834.000 -27.4%
2021 1.497.334.000 -0.03%
2022 1.598.898.000 6.35%
2023 899.916.000 -77.67%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Genes Tech Group Holdings Company Limited Research and Development Expenses
Year Research and Development Expenses Growth
2014 5.078.000
2015 3.652.000 -39.05%
2016 4.514.000 19.1%
2017 1.606.000 -181.07%
2018 1.187.000 -35.3%
2019 1.223.000 2.94%
2020 1.078.000 -13.45%
2021 1.500.000 28.13%
2022 1.150.000 -30.43%
2023 940.000 -22.34%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Genes Tech Group Holdings Company Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 70.839.000
2015 107.685.000 34.22%
2016 139.122.000 22.6%
2017 131.673.000 -5.66%
2018 133.165.000 1.12%
2019 173.231.000 23.13%
2020 173.312.000 0.05%
2021 185.724.000 6.68%
2022 130.306.000 -42.53%
2023 125.952.000 -3.46%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Genes Tech Group Holdings Company Limited EBITDA
Year EBITDA Growth
2014 81.390.000
2015 92.832.000 12.33%
2016 61.155.000 -51.8%
2017 80.701.000 24.22%
2018 116.400.000 30.67%
2019 301.943.000 61.45%
2020 251.711.000 -19.96%
2021 180.348.000 -39.57%
2022 -23.162.000 878.64%
2023 65.448.000 135.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Genes Tech Group Holdings Company Limited Gross Profit
Year Gross Profit Growth
2014 157.152.000
2015 214.996.000 26.9%
2016 234.982.000 8.51%
2017 237.159.000 0.92%
2018 256.086.000 7.39%
2019 488.708.000 47.6%
2020 399.924.000 -22.2%
2021 342.173.000 -16.88%
2022 107.483.000 -218.35%
2023 251.156.000 57.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Genes Tech Group Holdings Company Limited Net Profit
Year Net Profit Growth
2014 55.241.000
2015 61.570.000 10.28%
2016 12.111.000 -408.38%
2017 37.463.000 67.67%
2018 55.601.000 32.62%
2019 179.032.000 68.94%
2020 144.201.000 -24.15%
2021 79.403.000 -81.61%
2022 -80.436.000 198.72%
2023 28.556.000 381.68%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Genes Tech Group Holdings Company Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Genes Tech Group Holdings Company Limited Free Cashflow
Year Free Cashflow Growth
2014 29.223.000
2015 101.252.000 71.14%
2016 -132.778.000 176.26%
2017 -25.814.000 -414.36%
2018 118.226.000 121.83%
2019 -48.972.500 341.41%
2019 -195.890.000 75%
2020 26.072.000 851.34%
2021 248.852.000 89.52%
2022 64.427.000 -286.25%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Genes Tech Group Holdings Company Limited Operating Cashflow
Year Operating Cashflow Growth
2014 34.560.000
2015 113.555.000 69.57%
2016 -102.430.000 210.86%
2017 -23.346.000 -338.75%
2018 143.805.000 116.23%
2019 -34.333.000 518.85%
2019 -137.332.000 75%
2020 63.560.000 316.07%
2021 254.139.000 74.99%
2022 82.493.000 -208.07%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Genes Tech Group Holdings Company Limited Capital Expenditure
Year Capital Expenditure Growth
2014 5.337.000
2015 12.303.000 56.62%
2016 30.348.000 59.46%
2017 2.468.000 -1129.66%
2018 25.579.000 90.35%
2019 14.639.500 -74.73%
2019 58.558.000 75%
2020 37.488.000 -56.2%
2021 5.287.000 -609.06%
2022 18.066.000 70.74%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Genes Tech Group Holdings Company Limited Equity
Year Equity Growth
2014 221.342.000
2015 252.912.000 12.48%
2016 248.742.000 -1.68%
2017 468.692.000 46.93%
2018 488.170.000 3.99%
2019 626.238.000 22.05%
2020 770.052.000 18.68%
2021 801.210.000 3.89%
2022 712.509.000 -12.45%
2023 805.612.000 11.56%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Genes Tech Group Holdings Company Limited Assets
Year Assets Growth
2014 1.069.800.000
2015 1.547.992.000 30.89%
2016 1.218.227.000 -27.07%
2017 1.583.502.000 23.07%
2018 2.547.600.000 37.84%
2019 2.493.789.000 -2.16%
2020 2.462.524.000 -1.27%
2021 2.562.613.000 3.91%
2022 2.483.320.000 -3.19%
2023 2.102.883.000 -18.09%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Genes Tech Group Holdings Company Limited Liabilities
Year Liabilities Growth
2014 848.458.000
2015 1.295.080.000 34.49%
2016 969.485.000 -33.58%
2017 1.114.810.000 13.04%
2018 2.059.430.000 45.87%
2019 1.867.551.000 -10.27%
2020 1.692.472.000 -10.34%
2021 1.761.403.000 3.91%
2022 1.770.811.000 0.53%
2023 1.297.271.000 -36.5%

Genes Tech Group Holdings Company Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.01
Net Income per Share
0.06
Price to Earning Ratio
7.93x
Price To Sales Ratio
0.48x
POCF Ratio
-16.01
PFCF Ratio
-15.31
Price to Book Ratio
0.61
EV to Sales
0.96
EV Over EBITDA
9.55
EV to Operating CashFlow
-31.87
EV to FreeCashFlow
-30.47
Earnings Yield
0.13
FreeCashFlow Yield
-0.07
Market Cap
0,49 Bil.
Enterprise Value
0,97 Bil.
Graham Number
1.06
Graham NetNet
-0.5

Income Statement Metrics

Net Income per Share
0.06
Income Quality
-0.5
ROE
0.08
Return On Assets
0.03
Return On Capital Employed
0.1
Net Income per EBT
0.71
EBT Per Ebit
0.86
Ebit per Revenue
0.1
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.23
Operating Profit Margin
0.1
Pretax Profit Margin
0.09
Net Profit Margin
0.06

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
-0.05
Capex to Revenue
0
Capex to Depreciation
0.27
Return on Invested Capital
0.05
Return on Tangible Assets
0.03
Days Sales Outstanding
64.95
Days Payables Outstanding
50.73
Days of Inventory on Hand
475.69
Receivables Turnover
5.62
Payables Turnover
7.19
Inventory Turnover
0.77
Capex per Share
0

Balance Sheet

Cash per Share
0,15
Book Value per Share
0,81
Tangible Book Value per Share
0.72
Shareholders Equity per Share
0.81
Interest Debt per Share
0.65
Debt to Equity
0.79
Debt to Assets
0.3
Net Debt to EBITDA
4.75
Current Ratio
1.46
Tangible Asset Value
0,72 Bil.
Net Current Asset Value
0,33 Bil.
Invested Capital
920794000
Working Capital
0,51 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,09 Bil.
Average Payables
0,05 Bil.
Average Inventory
510650000
Debt to Market Cap
1.3

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Genes Tech Group Holdings Company Limited Dividends
Year Dividends Growth
2018 0
2019 0 0%
2021 0 0%

Genes Tech Group Holdings Company Limited Profile

About Genes Tech Group Holdings Company Limited

Genes Tech Group Holdings Company Limited, an investment holding company, provides turnkey solutions and trades in used semiconductor manufacturing equipment (SME) and parts. Its services include tool relocation, tool refurbishment, equipment module modification, repairmen, and parts supply of SME. The company provides SME and parts, such as furnaces, clean tracks, and other semiconductor equipment used in semiconductor manufacturing process, which includes wafer fabrication, deposition, photoresist coating, and development; and manufactures and sells heating jackets. It operates in Taiwan, Mainland China, South Korea, the United States, Japan, Singapore, and internationally. The company was founded in 2002 and is headquartered in Zhubei, Taiwan.

CEO
Mr. Ming-Hsiang Yang
Employee
262
Address
No. 80, Baotai 3rd Road
Zhubei, 30244

Genes Tech Group Holdings Company Limited Executives & BODs

Genes Tech Group Holdings Company Limited Executives & BODs
# Name Age
1 Ms. Hung-Li Wei
Chief Financial Officer, Compliance Officer, China Region GM & Executive Director
70
2 Mr. Ming-Hsiang Yang
Chairman & Chief Executive Officer
70
3 Ms. Wing Yan Yuen FCIS, FCS
Company Secretary
70
4 Mr. Ting-Kuo Chiang
Executive Director
70

Genes Tech Group Holdings Company Limited Competitors